EUVIMEDEUVIMED entdecken
Crossref

The clinical utility of neostigmine administration in the diagnosis of acquired myasthenia gravis

Harry Cridge iD, Alison Little, Roberto José-López, Theresa Pancotto, Jennifer R Michaels, Marika Menchetti, Anna Suñol, David Lipsitz, Michaela J Beasley

Journal of Veterinary Emergency and Critical Care · 2021-09 · 31 (5) · 647-655

DOI: 10.1111/vec.13097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Emergency and Critical Care, online erschienen am 29.07.2021. Verfasst von Harry Cridge und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi, Mississippi, 39762, USA. Hauptthemen laut MEDLINE: Cat Diseases, Dog Diseases, Myasthenia Gravis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the clinical utility of neostigmine methylsulfate administration in the diagnosis of suspected acquired myasthenia gravis (MG) in dogs and cats.

Design

Retrospective study (2017‐2019).

Setting

Five university teaching hospitals and 2 private referral hospitals. Animals Twenty‐two dogs and 3 cats. Criteria for inclusion were clinical signs consistent with acquired MG, performance of a neostigmine challenge and acetylcholine receptor antibody titers.

Interventions

None. Measurements & main results The route of neostigmine administration was recorded. Response to neostigmine challenge was determined via sequential evaluation of muscle strength and ambulation following administration of neostigmine methylsulfate. Response to neostigmine challenge was compared to acetylcholine receptor antibody titers, which were used as the biochemical gold standard in this study. Sixteen out of 22 dogs were diagnosed with acquired MG. Thirteen of 16 had a strong positive response to neostigmine challenge whereas 3 of 16 had no response. Two out of 3 dogs with polymyositis also had a strong positive response to neostigmine challenge. Weak positive results were seen with intracranial neoplasia ( n = 1) and a dog with dilated cardiomyopathy and coxofemoral joint disease ( n = 1). One cat was diagnosed with acquired MG and had a positive response to neostigmine challenge. Two cats had no response to neostigmine challenge and were diagnosed with alternate conditions. Two cats were premedicated with glycopyrrolate, one of which had a mild adverse response to neostigmine challenge (sialorrhea and mild transient tremors). Three out of 22 dogs had minimal adverse effects (sialorrhea and 1 dog with muscle tremors).

Conclusions

The neostigmine challenge appears to be safe and viable alternative to the previously utilized edrophonium challenge, particularly when weak positive responses are considered negative for acquired MG. Polymyositis cases may have a false positive response to neostigmine challenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cat DiseasesDog DiseasesMyasthenia GravisAnimalsCatsDogsNeostigmineRetrospective Studies

Stichwörter der Autor:innen

acetylcholine receptorcatsdiagnosticsdogsneuromuscular disorder

Substanzen

Neostigmine

Autor:innen und Institutionen

  • Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi, Mississippi, 39762, USA.
  • School of Veterinary Medicine, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, G61 1QH, UK.
  • Auburn University College of Veterinary Medicine, Auburn, AL 36849.
  • MSPCA - Angell Animal Medical Center, Boston, Massachusetts, 02130, USA.
  • Neurology and Neurosurgery Division, San Marco Veterinary Clinics, Veggiano, Italy.
  • Hospital for Small Animals, The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, EH25 9RG, UK.

ORCID-Profile: Harry Cridge

Zitieren

APA

Cridge, H., Little, A., José-López, R., Pancotto, T., Michaels, J. R., Menchetti, M., Suñol, A., Lipsitz, D., & Beasley, M. J. (2021). The clinical utility of neostigmine administration in the diagnosis of acquired myasthenia gravis. Journal of Veterinary Emergency and Critical Care, 31(5), 647-655. https://doi.org/10.1111/vec.13097

Vancouver

Cridge H, Little A, José-López R, Pancotto T, Michaels JR, Menchetti M, et al. The clinical utility of neostigmine administration in the diagnosis of acquired myasthenia gravis. Journal of Veterinary Emergency and Critical Care. 2021;31(5):647-655. doi:10.1111/vec.13097

BibTeX
@article{Cridge2021,
  author = {Cridge, Harry and Little, Alison and José-López, Roberto and Pancotto, Theresa and Michaels, Jennifer R and Menchetti, Marika and Suñol, Anna and Lipsitz, David and Beasley, Michaela J},
  title = {The clinical utility of neostigmine administration in the diagnosis of acquired myasthenia gravis},
  journal = {Journal of Veterinary Emergency and Critical Care},
  year = {2021},
  volume = {31},
  number = {5},
  pages = {647--655},
  doi = {10.1111/vec.13097}
}
Kostenlos starten →